Clinical Trial

Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to evaluate the efficacy of NBI-1065890 compared with placebo for the treatment of tardive dyskinesia (TD) in adult participants.
Protocol Amendment History 3 changes
notable Trial sites expanded: 6 -> 17 locations 2026-05-20
critical Recruitment opened 2026-04-25
notable Trial sites expanded: 0 -> 6 locations 2026-04-25
Trial Details
NCT Number NCT07365462
Lead Sponsor Neurocrine Biosciences
Conditions Tardive Dyskinesia
Enrollment 100 participants
Start Date 2026-02-06
Primary Completion 2027-02 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-06-23